Syndax Pharmaceuticals, Inc.SNDXNASDAQ
LOADING
|||
EPS Growth Trend
Above historical average.
Left:
||||
Year-over-year earnings per share growth rate
Latest
15.66%
↑ 115% above average
Average (39q)
7.28%
Historical baseline
Range
High:552.50%
Low:-187.34%
CAGR
-1.8%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 15.66% |
| Q2 2025 | 16.16% |
| Q1 2025 | 10.00% |
| Q4 2024 | -12.24% |
| Q3 2024 | -22.50% |
| Q2 2024 | 5.88% |
| Q1 2024 | 15.00% |
| Q4 2023 | -36.99% |
| Q3 2023 | -14.06% |
| Q2 2023 | -8.47% |
| Q1 2023 | 4.84% |
| Q4 2022 | -6.90% |
| Q3 2022 | 6.45% |
| Q2 2022 | 1.59% |
| Q1 2022 | -134.81% |
| Q4 2021 | 552.50% |
| Q3 2021 | 9.09% |
| Q2 2021 | 18.52% |
| Q1 2021 | -22.73% |
| Q4 2020 | 4.35% |
| Q3 2020 | -9.52% |
| Q2 2020 | 4.55% |
| Q1 2020 | 0.00% |
| Q4 2019 | -7.32% |
| Q3 2019 | 12.77% |
| Q2 2019 | 11.32% |
| Q1 2019 | 24.29% |
| Q4 2018 | -2.94% |
| Q3 2018 | 8.11% |
| Q2 2018 | 6.33% |
| Q1 2018 | 1.25% |
| Q4 2017 | -17.65% |
| Q3 2017 | 2.86% |
| Q2 2017 | 1.41% |
| Q1 2017 | -20.34% |
| Q4 2016 | 29.76% |
| Q3 2016 | -78.72% |
| Q2 2016 | 79.30% |
| Q1 2016 | -187.34% |
| Q4 2015 | 31.90% |